Patrys
- Short interest
- 0.00%
- −0.01 pp 30d
- as of 24 Jan 2025
- Reported shorts
- 39K
- Shares on issue
- 2.057B
Patrys (PAB) News
Latest articles and price-sensitive announcements with AI sentiment classification.
ASX
KalkinePatrys Limited Announces 2026 AGM Date and Director Nomination Deadline
Patrys Limited (ASX:PAB), a biotechnology firm advancing its deoxymab platform of cell-penetrating antibodies, has revealed that its Annual General Meeting is scheduled for Monday, 30 November 2026, with director nominations closing on Monday, 12 October 2026. Key Points Patrys Limited's Annual General Meeting set for Monday, 30 November 2026 Director nomination submissions must be received by Monday, 12 October 2026 at 5:00pm WST Nominations are to be submitted to the Company’s registered ...
Date of AGM and Closing Date for Director Nominations
other announcement
Notification of cessation of securities - PAB
other announcement
Patrys Completes Cohort 1 Dosing and Follow-Up
other announcement
Appendix 4G and Corporate Governance Statement
other announcement
First Participants Dosed in RLS-2202 Phase 1A Clinical Trial
other announcement
What Is Putting Patrys (ASX:PAB) in the Spotlight Today?
Highlights Patrys is in focus after formation of a new clinical advisory committee. The update keeps attention on biotechnology and the companys next operational steps. The broader Healthcare Stocks theme remains centred on execution, disclosure quality and strategic follow-through. Further company updates will help clarify how todays development fits into the longer operating pathway. Patrys (ASX:PAB) is drawing attention today after formation of a new clinical advisory committee. The develo...
PAB Establishes Clinical Advisory Committee
other announcement
Appendix 4E - Preliminary Final Report
other announcement
Ethics Approval Secured for Phase 1A Clinical Trial
other announcement
Google NewsPatrys (ASX:PAB) Holds Firm: Could the Small-Cap Biotechnology Stock Deliver a New Clinical Catalyst? - Kalkine
Patrys (ASX:PAB) Holds Firm: Could the Small-Cap Biotechnology Stock Deliver a New Clinical Catalyst? Kalkine
Patrys Secures 50% Revenue Share in IP Commercialisation
earnings announcement
Change of Director's Interest Notices x4
director_dealing announcement
Patrys (ASX:PAB) Shares Climb Following Key Clinical Trial Milestone - Kalkine
Patrys (ASX:PAB) Shares Climb Following Key Clinical Trial Milestone Kalkine
Patrys advances RLS-2202 toward Phase 1 Clinical Trial
other announcement
$3.2 million Placement to Advance Clinical Trials
capital_raise announcement
RLS-2201 Manufacturing and Regulatory Pathway Initiated
other announcement
Appendix 4D - Half Year Accounts - 31 December 2025
other announcement
Change of Director's Interest Notice - BL
director_dealing announcement
Completion of Acquisition and Board Appointments
takeover announcement